Roche moved to secure a late-stage competitive position in BTK degradation by paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg. The deal puts Roche in the center of an impending phase 3 showdown against Eli Lilly’s Jaypirca, with both strategies targeting a common clinical need in B-cell malignancies. The agreement highlights how BTK modality competition is shifting toward protein degradation, with companies betting on differentiated duration and tolerability profiles to win line-of-therapy share. For investors, the headline figure is the upfront structure—signaling confidence that the program can clear the key efficacy and safety gates. For biotech strategists, the move also shows how Big Pharma is using targeted licensing to quickly build late-phase portfolios while preserving optionality for future combinations and next-gen chemistry.